Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.
about
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patientsContributions of human enzymes in carcinogen metabolismGenetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.Accelerator mass spectrometry-enabled studies: current status and future prospects.Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsivenessPotential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride.Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies.Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.Genotoxic mechanism of tamoxifen in developing endometrial cancer.Drug bioactivation, covalent binding to target proteins and toxicity relevance.The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines.Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs.Cytochrome P450/redox partner fusion enzymes: biotechnological and toxicological prospects.Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.Recent advances in biomedical applications of accelerator mass spectrometry.Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?Is tamoxifen a genotoxic carcinogen in women?Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.The effect of chlorpyrifos-oxon and other xenobiotics on the human cytochrome P450-dependent metabolism of naphthalene and deet.
P2860
Q24810279-0B37CA8F-1635-416A-97DA-D22A588645B8Q30520640-94ABE527-68FB-46FB-8A6C-4A47426B4BFCQ33289676-B0C2CC3D-E769-4168-98B9-4685F5C598FAQ33819361-50161F32-C151-47BE-B680-DCFA6E2B1640Q34038020-577D689C-55DD-47D6-8B94-7AD173D3097CQ34774040-F9986A2F-D2BB-4BAC-9D99-430FDE247ED5Q35008045-1E049DBE-20AD-4BDF-B06B-3778E776DD43Q35086803-30CAEB32-5769-488B-A0E9-A414D493180AQ35608859-290A112E-60F9-4A8E-9673-5D6D0BCF225EQ35825872-8F6E5C50-D4C0-4A52-A2DF-8FC72560DDA2Q35828013-A8E51DBC-1DAB-41BD-9CA6-8E39EC0BA762Q36061821-7FF34B23-5A65-455D-96AC-6BFD9581C8E6Q36473486-B87C361F-FE76-408A-A98E-C3A819781E12Q36847276-AF873138-02DF-4ED4-B78B-31C88DBCAFD8Q37008895-EBA656AE-F10C-45B6-A403-06C2BCA51A6AQ37221922-E0F4EB3E-75C3-4782-85A2-917536624513Q37266360-38B3F05C-9FBC-4F68-9DAD-00DBCA188732Q37271799-EF20B8E9-6E29-4DA2-9FC7-AA91211AC346Q37511330-EC2B77DD-638A-4AC0-820D-CF7AADEFF770Q38105253-36995A43-303A-402F-AABD-44D98D51D4E2Q38442184-6A785D5F-CA8F-4A8F-B26A-97FAF62BE5FFQ38629670-D7613268-3520-4625-820E-103458D29E0EQ43121565-EC8FB838-0591-49F0-A0C7-DE4ED6C6B8B6Q44873691-C0A00A34-A483-4DD3-951F-F24D8BAE010F
P2860
Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Identification of human CYP fo ...... d irreversible binding to DNA.
@ast
Identification of human CYP fo ...... d irreversible binding to DNA.
@en
type
label
Identification of human CYP fo ...... d irreversible binding to DNA.
@ast
Identification of human CYP fo ...... d irreversible binding to DNA.
@en
prefLabel
Identification of human CYP fo ...... d irreversible binding to DNA.
@ast
Identification of human CYP fo ...... d irreversible binding to DNA.
@en
P2093
P356
P1433
P1476
Identification of human CYP fo ...... d irreversible binding to DNA.
@en
P2093
Anthony H Gibbs
Esther Sanchez
Ian N H White
Karen Brown
Kenneth W Turteltaub
P304
P356
10.1093/CARCIN/23.11.1897
P407
P577
2002-11-01T00:00:00Z